Peter John Pugh

Peter John Pugh

Auto-generated profile, based on publicly available information

Peter John Pugh

Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2023 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PCPanagiota Anna Chousou
Panagiota Anna Chousou
RCRahul Chattopadhyay
Rahul Chattopadhyay
VTVasiliki Tsampasian
Vasiliki Tsampasian
VVVassilios S. Vassiliou
Vassilios S. Vassiliou
PPPeter John Pugh
Peter John Pugh
Background: Atrial fibrillation (AF) is the most common pathological arrhythmia, and its complications lead to significant morbidity and mortality. However, patients with AF can often go undetected, especially if they are asymptomatic or have a low burden of paroxysms. Identification of those at high risk of AF development may help refine screening and management strategies. Methods: PubMed and Embase databases were systematically searched for studies looking at electrocardiographic predictors of AF from inception to August 2021. Results: A total of 115 studies were reported which examined a combination of atrial and ventricular parameters that could be electrocardiographic predictors of AF. Atrial predictors include conduction parameters, such as the PR interval, p-wave index and dispersion, and partial interatrial or advanced interatrial block, or morphological parameters, such as p-wave axis, amplitude and terminal force. Ventricular predictors include abnormalities in QRS amplitude, morphology or duration, QT interval duration, r-wave progression and ST segment, i.e., t-wave abnormalities. Conclusions: There has been significant interest in electrocardiographic prediction of AF, especially in populations at high risk of atrial AF, such as those with an embolic stroke of undetermined source. This review highlights the breadth of possible predictive parameters, and possible pathological bases for the predictive role of each parameter are proposed.

21 March 2011 in EP Europace
Verified
Journal Article
Open access
PDF file
FKFakhar Z. Khan
Fakhar Z. Khan
MVMunmohan S. Virdee
Munmohan S. Virdee
PRPhilip A. Read
Philip A. Read
PPPeter J. Pugh
Peter J. Pugh
DBDavid Begley
David Begley
DDDavid P. Dutka
David P. Dutka
Left ventricular (LV) lead placement to the most delayed segment offers the greatest potential benefit to cardiac resynchronization therapy (CRT). We assessed the impact of interventricular (VV) optimization on acute changes in cardiac output (CO) in patients with and without LV pacing of the most delayed segment. In 124 patients, the most delayed segment was defined by speckle tracking radial strain and the LV lead position by biplane fluoroscopy. Patients were classified as either a concordant (LV lead at latest site), adjacent (within one segment), or remote (two or more segments away) LV lead. Atrioventricular (AV) and VV delays were optimized by echocardiography. Cardiac output was measured non-invasively and a >20% increase in CO from baseline (intrinsic) defined acute response. Changes in CO in patients with concordant, adjacent, or remote LV leads were recorded following atrioventricular optimization alone (AV OPT) and after combined AV and VV optimization (AV/VV OPT). Compared with AV OPT pacing, AV/VV OPT produced a greater rise in CO (5.45 ± 1.1 vs. 5.76 ± 1.2 L/min, P< 0.001) and higher acute response rates (48.4 vs. 61.3%, P= 0.041). In adjacent patients, compared with AV OPT pacing, AV/VV OPT settings increased the response rate from 36.4 to 63.6% (P= 0.037). VV optimization had no effect on acute response rates in patients with remote (26.7 vs. 33.3%, P = 0.581) or concordant LV leads (65.6 vs. 72.1%, P = 0.438). VV optimization overcomes some but not all of the deleterious effects of a suboptimal LV lead position.

1 February 2010 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
VNVikrant Nayar
Vikrant Nayar
PPPeter J Pugh
Peter J Pugh
Heart failure is posing an increasing burden on healthcare systems around the world, a consequence of increased survival from acute coronary syndromes and life-prolonging medications. Cardiac resynchronization therapy has become a ratified and established therapy for heart failure to reduce both the morbidity and mortality of the condition. Its prophylactic role in patients who have minimal symptoms to delay future deterioration is a novel development. The indications for this therapy continue to evolve, mainly as a result of company-sponsored multicenter trial data aimed at broadening its usage. Uncertainty remains on how to accurately identify individuals who will respond to resynchronization therapy and how best to manage patients following device implant.

21 May 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
VNVikrant Nayar
Vikrant Nayar
BSBhavana Singh
Bhavana Singh
PPPeter J. Pugh
Peter J. Pugh
A 59-year-old Afro-Caribbean woman with a history of tuberculosis, hepatitis C, and excessive alcohol consumption presented to our institution for investigation of her breathlessness, worsening peripheral oedema, acute renal failure, and deranged liver function tests. She had elevated jugular venous pressure, hepatomegaly, gross peripheral oedema, ascites, and signs of chronic liver disease. Despite diuretic therapy and oral fluid restriction, her oedema persisted. Echocardiography demonstrated normal biventricular size and function with no valve pathology. In addition, a large homogeneous mass was seen in the right atrium (Panel A), with finger-like projections extending into the right ventricle during atrial systole and caudal extension into the inferior vena cava (Panel B). She had neither a central venous catheter nor other obvious prothrombotic cause for atrial thrombus formation. It was initially proposed that the mass was most likely atrial myxoma in an unusual position. Ultrasound of the liver, however, demonstrated several nodules consistent with malignancy (Panel C). Computed tomography demonstrated the typical appearance of hepatocellular carcinoma, with associated thrombus, extending from the right lobe of the liver into the hepatic vein and inferior vena cava and into the right atrium (Panel D). Multiple pulmonary nodules, in keeping with pulmonary metastases, and bilateral pulmonary emboli were also seen. She remained unresponsive to diuretic therapy and was discharged home for palliative care.

1 March 2018 in Future Cardiology
Verified
Journal Article
Closed access
PCPanagiota Anna Chousou
Panagiota Anna Chousou
PPPeter J Pugh
Peter J Pugh
A substantial proportion of patients who undergo cardiac device implantation receive oral anticoagulation to prevent thromboembolism or antiplatelets to prevent thrombotic events. Anticoagulation and antiplatelets increase the risk of hemorrhagic complications, while discontinuation may increase thromboembolic risk and thrombotic events. With the introduction of non-vitamin K antagonist oral anticoagulant agents and the newer antiplatelet agents such as prasugrel or ticagrelor, the perioperative management of patients has become more challenging. In this article, we review the recent trials and meta-analysis and describe the available evidence, as well as the current recommendations in order to inform best practice. We also reinforce the importance of further trials in this complex and rapidly evolving area.

18 September 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SRS. Ashwin Reddy
S. Ashwin Reddy
MPMarta Peverelli
Marta Peverelli
TMTobias MacCarthy
Tobias MacCarthy
JVJohnathan Vibhishanan
Johnathan Vibhishanan
SASharad Agarwal
Sharad Agarwal
PCPatrick A. Calvert
Patrick A. Calvert